Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. director reports no share ownership in initial filing. A director of Zoetis Inc. (ZTS) filed an initial beneficial ownership statement on Form 3, indicating that they currently hold no non-derivative Zoetis securities, with Table I showing "No securities beneficially held" and an amount of 0. The filing also shows no derivative securities such as options or warrants listed in Table II. The form is filed by a single reporting person and is signed by an attorney-in-fact on their behalf.
Zoetis Inc. disclosed a Form 4 reporting an equity award to one of its directors. On 12/01/2025, the director received 1,964 restricted stock units (RSUs) under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan at an exercise price of $127.25 per unit.
Each RSU represents a contingent right to receive one share of Zoetis common stock. The RSUs are scheduled to vest and be settled in Zoetis common shares on the first anniversary of the grant date, December 1, 2025, provided the director continues to serve through that date, with potential earlier vesting upon certain specified events.
Zoetis Inc. announced that it will host an Innovation Webcast at 8:30 a.m. ET on December 2, 2025. The webcast will feature a company presentation focused on its innovation-related topics in animal health. The presentation materials for this event are provided as an exhibit to the report, giving investors and stakeholders access to the same information shared during the webcast.
Zoetis Inc. filed its Q3 2025 report, showing steady growth. Revenue was $2.4 billion versus $2.388 billion a year ago, and diluted EPS reached $1.63 compared with $1.50. Net income attributable to Zoetis rose to $721 million from $682 million as cost of sales declined and operating expenses remained well managed. For the first nine months, revenue was $7,080 million versus $6,939 million, with diluted EPS of $4.65 versus $4.18.
Companion animal products continued to lead, with Q3 category revenue of $1,652 million, while livestock was $725 million. By product, parasiticides ($564 million), vaccines ($496 million), and dermatology ($472 million) were top contributors. Cash and cash equivalents were $2,084 million, and long-term debt (net) was $7,069 million after issuing $1.85 billion of new senior notes to redeem 2025 maturities. The company repurchased $381 million of shares in Q3 and $1,169 million year to date. The effective tax rate improved to 18.7% from 20.8%.
Zoetis Inc. (ZTS) furnished an update on its business by reporting third-quarter 2025 results and full-year 2025 guidance. The company announced these details in a press release dated November 4, 2025, which is provided as Exhibit 99.1.
The disclosure is presented under Item 2.02: Results of Operations and Financial Condition and is furnished, not filed, under the Exchange Act. This means it is not subject to Section 18 liabilities and is not incorporated by reference unless specifically stated. The filing confirms Zoetis’ common stock trades on the NYSE under the symbol ZTS.
Zoetis (ZTS) appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025. The Board will increase from 12 to 13 members on that date.
The company states the appointment was not made pursuant to any third‑party arrangement and notes no related party transactions with Ms. Tilenius since the beginning of the last fiscal year. She will be eligible under Zoetis’ non‑employee director compensation program outlined in its 2025 proxy. Zoetis will enter into its standard indemnification agreement with her, and a press release announcing the appointment was issued on October 28, 2025.
Zoetis Inc. (ZTS) reported an insider transaction by an Executive Vice President. On 10/10/2025, the officer acquired 204.6185 phantom stock units at $46.71 per unit under the Zoetis Supplemental Savings Plan, bringing total derivative holdings to 10,990.0773 units (direct ownership).
The phantom units are cash-settled after separation from service. Each unit’s value tracks Zoetis common stock and includes a small cash-equivalent component typically around 5%.
Zoetis Inc. (ZTS) reported an insider transaction by an Executive Vice President. On 10/10/2025, the officer acquired 201.7367 phantom stock units under the Zoetis Supplemental Savings Plan at a reported price of $46.71 per unit. Following the transaction, the officer beneficially owns 387.6519 phantom stock units, held directly.
These phantom stock units are settled in cash after separation from service and their value is determined by the market value of Zoetis common stock plus a small cash-equivalent component that typically represents around 5% of the unit’s value.
Zoetis (ZTS) reported a Form 4 showing its Chief Financial Officer acquired 230.5564 phantom stock units on 10/10/2025 under the Zoetis Supplemental Savings Plan. These units are cash-settled after separation from service and track the value of Zoetis common stock plus a small cash-equivalent component.
The filing lists a $46.71 price for the derivative entry and references 76.3184 shares as the underlying amount for this transaction. Following the transaction, the officer held 6,585.9941 phantom stock units on a direct basis.
Zoetis (ZTS): On 10/10/2025, an executive officer reported acquiring 201.7366 phantom stock units under the Zoetis Supplemental Savings Plan at $46.71 per unit.
After this transaction, the officer directly holds 28,624.727 derivative units. These phantom stock units track the value of Zoetis common stock plus a small cash-equivalent component and are settled in cash following separation from service. For this grant, the filing lists 66.7785 underlying shares of common stock.